(NASDAQ: CLLS) Cellectis Sa's forecast annual revenue growth rate of 55.61% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.03%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.06%.
Cellectis Sa's revenue in 2024 is $24,410,000.On average, 2 Wall Street analysts forecast CLLS's revenue for 2024 to be $1,364,581,504, with the lowest CLLS revenue forecast at $472,462,028, and the highest CLLS revenue forecast at $2,256,700,981. On average, 2 Wall Street analysts forecast CLLS's revenue for 2025 to be $1,753,667,880, with the lowest CLLS revenue forecast at $694,797,100, and the highest CLLS revenue forecast at $2,812,538,661.
In 2026, CLLS is forecast to generate $5,705,951,704 in revenue, with the lowest revenue forecast at $5,108,704,117 and the highest revenue forecast at $6,303,199,291.